Fundamental Analysis of Entrada Therapeutics Inc - Growth / Value Index
TRDA - Valuation Highlights
Valuation Analysis
Book Value in last 3 years is trending down
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 21.53 | -22757.20 | -458918.60 % | |
| Price to Book | 2.12 | 2044.17 | 92525.90 % | 1.87 |
| Price to Sales | 3.10 | 5683.75 | 30506.62 % | |
| Enterprise Value to EBITDA Multiple | 16.07 | -25882.47 | -538328.20 % |
TRDA - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Good Score of 66.88
Piotroski F Score - Stable Value of 5.0
Good Net Margin of 14.42% is achieved by the company
Very Low Dividend Yield of 0 %
Low Earning Yield of 4.91 %
Negative Net profit for last two years
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 9.83 | -8.98 | 79.82 % | 8.72 |
| Return On Asset | 4.82 | -4.64 | 87.64 % | 4.60 |
| Net Profit Margin | 14.42 | -24.98 | 93.33 % | 39.74 |
| Operating Profit Margin | 14.57 | -38.60 | 89.97 % | 35.71 |
| EBITDA Margin | 17.06 | -21.96 | 93.83 % | 41.32 |
Highlights
| Market Cap | 506047 K |
| Enterprise Value | 446354 K |
| Price/Book TTM | 2.12 |
| Outstanding Share | 33759.00 K |
| Float/ Outstanding Share | 39.17% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 44.22 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 5.00 |
| Altman Z Score | 1.33 |
| Sloan Ratio | -0.295 |
| Peter Lynch Fair Value | 6.92 |
TRDA - Growth Highlights
Growth Analysis
STRONG JUMP IN NET SALE : YoY growth
Annual sales of the company is increased for three years in a row
Steady increase in Total Assets for last 3 Years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 162873 K | 245.07 % | 41.27 % |
| Gross Profit | 161203 K | 6908.07 % | 41.53 % |
| EBITDA | 27784.00 K | 78.72 % | 333.08 % |
| Net Profit | 23485.00 K | 76.99 % | 346.19 % |
| EPS | 0.696 | 99.98 % | NA |
TRDA - Stability Highlights
Stability Analysis
Tsr Stability Index - Good Score of 66.07
Altman Z Score of 1.26 suggest high risk
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.0326 | -17.48 % | 0.0308 |
| Cash Ratio | 2.22 | -74.19 % | |
| Quick Ratio | 2.33 | 0 % | 2.38 |
| Shareholders Equity | 51.65 | -38.75 % | |
| Debt to EBITDA | -0.413 | -342.14 % |
Historical Valuation Ratios of Entrada Therapeutics Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Entrada Therapeutics Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Entrada Therapeutics Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Entrada Therapeutics Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)